Methadone and buprenorphine treatments in patients with schizophrenia

Schizophrenia Research, 2019, sous presse

Dervaux A (1), Plancke L (2,3), Amariei A (2), Trouiller P (3), Tahon M (4), P.Martinetti M (5), Naassila M (6), Cottencin O (7), Danel T (2). Methadone and buprenorphine treatments in patients with schizophrenia, Schizophrenia Research, sous presse

  • (1) Service de Psychiatrie et Addictologie de liaison, CHU Sud, 80054 Amiens Cedex, France
  • (2) Fédération Régionale de Recherche en Psychiatrie et Santé Mentale Hauts-de-France, Lille, France
  • (3) Centre lillois d'études sociologiques et économiques, Villeneuve d'Ascq, France
  • (4) Direction régionale du service du contrôle médical de l'assurance-maladie des Hauts-de-France, France
  • (5) The College of NewJersey, Department of Psychology, Ewing, NJ 08618, USA
  • (6) Université de Picardie Jules Verne, Groupe de Recherche sur l'Alcool & les Pharmacodépendances (GRAP) INSERM U1247, France
  • (7) Univ. Lille, CNRS UMR 9193 SCALab (Sciences Cognitives et Sciences Affectives) & CHU Lille, Department of Psychiatry and Addiction Medicine, F-59000 Lille, France. Service d'Addictologie, Hôpital Fontan 2, 59000 Lille, France

Schizophrenia is associated with high rates of nicotine, cannabis, alcohol, and cocaine use disorders (Volkow, 2009); however, very few
studies have assessed the frequency of opioid use disorders (OUD) in patients with schizophrenia. In the NESARC study, respondents with schizophrenia had a lifetime frequency of heroin abuse or dependence of 1.1% (95% CI: 0.1–2.3), and OUD of 3.6%, (95% CI: 0.4–6.8), according to DSM-IV criteria (Martins and Gorelick, 2011). In clinical samples of patients with schizophrenia, the rates of OUD ranged from 0.5% to 13% (Table 1). To our knowledge, there is no study investigating the prevalence of opioid-agonist treatment among patients with schizophrenia in the community or in clinical samples.